Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Neurovascular unit dysfunction with blood-brain barrier hyperpermeability contributes to major depressive disorder: a review of clinical and experimental evidence.
Adherence Associated with Oral Medications in the Treatment of Spasticity.
IL-17A activates ERK1/2 and enhances differentiation of oligodendrocyte progenitor cells.
The interplay between bacillus Calmette-Guérin and Treg cells and its role to prevent or cure inflammatory diseases.
▼Teriflunomide for multiple sclerosis.
Hepatic but Not CNS-Expressed Human C-Reactive Protein Inhibits Experimental Autoimmune Encephalomyelitis in Transgenic Mice.
Characteristics of Patients with Relapsing Remitting Multiple Sclerosis Taking once Daily Teriflunomide Tablets in the United States.
[History of Guillain-Barré Syndrome].
Duality of Antidepressants and Neuroprotectants.
Signs of myelin impairment in cerebrospinal fluid after osmotic opening of the blood-brain barrier in rats.
A cost-effectiveness model for the use of a cannabis-derived oromucosal spray for the treatment of spasticity in multiple sclerosis.
Depression during multiple sclerosis relapse: relation to disability and relapse severity.
Association of TIM-1 5383-5397ins/del and TIM-3 -1541C>T polymorphisms with multiple sclerosis in Isfahan population.
Interferon β-1a and Atorvastatin in the Treatment of Multiple Sclerosis.
Characteristics associated with drug-induced liver injury from interferon beta in multiple sclerosis patients.
Is a hypothetical melanoma-like neuromelanin the underlying factor essential for the aetiopathogenesis and clinical manifestations of multiple sclerosis?
Neuromyelitis optica: an often forgotten cause of intractable nausea and vomiting.
[Multiple sclerosis and physical activity : An historical perspective.]
Central nervous system infectious diseases mimicking multiple sclerosis: recognizing distinguishable features using MRI.
Immunoregulatory Effects of Interferon-β in Suppression of Th17 cells.
Acute demyelinating encephalomyelitis presenting with psychiatric symptoms.
Diffusion tensor imaging of the trigeminal nerve in patients with trigeminal neuralgia due to multiple sclerosis.
Canonical Wnt Signaling in Dendritic Cells Regulates Th1/Th17 Responses and Suppresses Autoimmune Neuroinflammation.
[Genome-wide association study as a method for genetic architecture analysis in polygenic diseases (by the example of multiple sclerosis)].
Pallidal and caudate volumes correlate with walking function in multiple sclerosis.
Pages
« first
‹ previous
…
672
673
674
675
676
677
678
679
680
…
next ›
last »